Mesoblast (MESO) Competitors $16.39 -0.60 (-3.50%) As of 02:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO vs. RYTM, AXSM, TLX, CRSP, PCVX, CYTK, MTSR, ADMA, KRYS, and AKROShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Cytokinetics (CYTK), Metsera (MTSR), ADMA Biologics (ADMA), Krystal Biotech (KRYS), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. Its Competitors Rhythm Pharmaceuticals Axsome Therapeutics Telix Pharmaceuticals CRISPR Therapeutics Vaxcyte Cytokinetics Metsera ADMA Biologics Krystal Biotech Akero Therapeutics Rhythm Pharmaceuticals (NASDAQ:RYTM) and Mesoblast (NASDAQ:MESO) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment. Does the media refer more to RYTM or MESO? In the previous week, Mesoblast had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 7 mentions for Mesoblast and 6 mentions for Rhythm Pharmaceuticals. Mesoblast's average media sentiment score of 0.60 beat Rhythm Pharmaceuticals' score of 0.15 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, RYTM or MESO? Mesoblast has lower revenue, but higher earnings than Rhythm Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$136.86M40.05-$260.60M-$2.81-30.66Mesoblast$5.67M369.25-$87.96MN/AN/A Do analysts prefer RYTM or MESO? Rhythm Pharmaceuticals presently has a consensus price target of $91.93, indicating a potential upside of 6.69%. Mesoblast has a consensus price target of $18.00, indicating a potential upside of 9.86%. Given Mesoblast's higher possible upside, analysts clearly believe Mesoblast is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in RYTM or MESO? 1.4% of Mesoblast shares are held by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is RYTM or MESO more profitable? Mesoblast has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -123.26%. Mesoblast's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-123.26% -739.62% -44.27% Mesoblast N/A N/A N/A Which has more volatility and risk, RYTM or MESO? Rhythm Pharmaceuticals has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. SummaryMesoblast beats Rhythm Pharmaceuticals on 11 of the 14 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.09B$3.04B$5.71B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A21.1328.0720.02Price / Sales369.25338.95459.47103.02Price / CashN/A43.2336.5558.97Price / Book3.898.278.615.88Net Income-$87.96M-$55.19M$3.24B$258.50M7 Day Performance4.90%5.50%3.83%2.03%1 Month Performance55.31%17.25%10.40%12.52%1 Year Performance120.82%4.61%34.13%19.07% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast0.8411 of 5 stars$16.39-3.5%$18.00+9.9%+113.6%$2.09B$5.67M0.0080Upcoming EarningsGap DownRYTMRhythm Pharmaceuticals3.1139 of 5 stars$89.15+2.8%$91.00+2.1%+76.9%$5.67B$130.13M-31.73140AXSMAxsome Therapeutics4.7409 of 5 stars$112.33+3.1%$172.33+53.4%+23.2%$5.53B$385.69M-19.47380Analyst RevisionTLXTelix PharmaceuticalsN/A$15.57-2.5%$22.33+43.4%N/A$5.27B$783.21M0.00N/ANews CoverageAnalyst RevisionCRSPCRISPR Therapeutics1.6674 of 5 stars$56.42-0.7%$71.75+27.2%+19.3%$4.87B$37.31M-12.48460Analyst ForecastGap UpPCVXVaxcyte1.8143 of 5 stars$36.38+1.3%$136.50+275.2%-57.4%$4.69BN/A-9.12160News CoveragePositive NewsCYTKCytokinetics4.2146 of 5 stars$38.58+4.2%$70.92+83.8%-34.3%$4.61B$18.47M-7.29250News CoverageMTSRMetseraN/A$42.47+8.1%$55.00+29.5%N/A$4.46BN/A0.0081Lockup ExpirationGap UpADMAADMA Biologics3.6054 of 5 stars$18.68+0.9%$27.67+48.1%+27.5%$4.46B$426.45M21.98530News CoverageKRYSKrystal Biotech4.8848 of 5 stars$150.41+1.5%$213.75+42.1%-27.4%$4.35B$290.52M36.16210News CoverageAnalyst ForecastAKROAkero Therapeutics3.7794 of 5 stars$52.73+2.2%$82.50+56.5%+88.3%$4.20BN/A-27.0430Positive News Related Companies and Tools Related Companies RYTM Competitors AXSM Competitors TLX Competitors CRSP Competitors PCVX Competitors CYTK Competitors MTSR Competitors ADMA Competitors KRYS Competitors AKRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MESO) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MESO Stock Alerts